In a 68-year-old patient with small‑vessel disease on brain MRI and no prior stroke, TIA, or atherosclerotic cardiovascular events, is aspirin indicated?

Aspirin is NOT indicated for primary prevention in a 68-year-old patient with small vessel disease on MRI who has no history of stroke, TIA, or atherosclerotic cardiovascular events.

The most recent and highest-quality evidence specifically addressing cerebral small vessel disease recommends AGAINST using aspirin in patients with covert cerebral small vessel disease (ccSVD) who have not had clinical events 1. This 2021 ESO guideline on covert cerebral small vessel disease explicitly states: "We do not recommend antiplatelet drugs such as aspirin in ccSVD."

Key Reasoning

Why Aspirin is Not Indicated

Small vessel disease on MRI without prior clinical events represents covert cerebral small vessel disease. The evidence shows:

• No proven benefit: There is no direct evidence that aspirin prevents stroke or cognitive decline in patients with radiographic small vessel disease alone 1
• Bleeding risk outweighs benefit: At age 68, the patient faces increased bleeding risk, particularly intracranial hemorrhage, which is especially concerning given the underlying small vessel disease 2, 3
• Recent primary prevention trials show harm: The 2018 ASPREE trial specifically studied patients ≥70 years and found no reduction in cardiovascular events or stroke with aspirin, but increased bleeding risk and mortality 4, 2

Current Guideline Framework

The 2024 AHA/ASA Primary Prevention of Stroke Guidelines provide clear direction 2:

• Class 3 (No Benefit): Aspirin is not beneficial to prevent first stroke in individuals ≥70 years with cardiovascular risk factors
• Class 2b (Not Well Established): Even in younger patients with diabetes or vascular risk factors and no prior stroke, aspirin's benefit is uncertain

When Aspirin WOULD Be Indicated

Aspirin becomes clearly indicated only with:

1. Prior ischemic stroke or TIA - then aspirin 75-325 mg daily is Class I recommendation 5, 6
2. Documented atherosclerotic cardiovascular disease (prior MI, coronary revascularization, symptomatic PAD) - aspirin 75-100 mg daily 7, 8
3. Lacunar stroke - antiplatelet monotherapy reduces recurrent stroke by 22% 6

Clinical Algorithm for This Patient

Does the patient have:

• Prior stroke/TIA? → NO → Aspirin not indicated
• Prior MI or coronary revascularization? → NO → Aspirin not indicated
• Symptomatic peripheral artery disease? → NO → Aspirin not indicated
• Only MRI findings of small vessel disease? → YES → Do NOT start aspirin

Important Caveats

Bleeding Risk Considerations

• Age >65 years increases bleeding risk substantially 3
• Small vessel disease itself may predispose to cerebral microbleeds and future intracerebral hemorrhage
• The number needed to treat to cause major bleeding (210) is lower than the number needed to prevent an ASCVD event (265) in primary prevention 4

What TO Do Instead

Focus on proven interventions for small vessel disease 1:

• Blood pressure control - well-controlled BP reduces ccSVD progression; lower targets may provide additional benefit
• Smoking cessation - health priority
• Regular exercise - may benefit cognition
• Healthy diet and lifestyle modifications
• Lipid management if indicated by cardiovascular risk

Common Pitfall to Avoid

Do not confuse radiographic small vessel disease with clinical cerebrovascular disease. The presence of white matter hyperintensities or lacunes on MRI alone does NOT constitute an indication for aspirin therapy. Aspirin is indicated for secondary prevention after clinical events, not for primary prevention based on imaging findings alone.